Celgene to Pay $1 Billion for Biotech Collaboration With Juno

As part of the deal, Celgene will acquire 9.1 million shares of Juno, a leader in cancer drugs that use patients’ immune systems to attack tumors.











from NYT > Technology http://ift.tt/1Huanol